Table 3 Cox proportional hazard regression analyses

T790M negative patients

PFS

 Age (≥ 75/ < 74)

0.52

(0.16, 1.68)

0.276

1.13

(0.18, 6.97)

0.897

 Gender (male/female)

1.84

(0.64, 5.32)

0.260

2.92

(0.57, 14.95)

0.198

 ECOG performance status (2-3/0-1)

4,18 × 10^–9

(0.00, INF)

0.998

7.19 × 10^–10

(0.00, INF)

0.998

 EGFR mutation status (L858R or other/exon 19 deletion)

2.20

(0.80, 6.02)

0.126

5.90

(1.22, 28.54)

0.027

 PE ( +/-)

0.81

(0.28, 2.33)

0.694

1.89

(0.38, 9.34)

0.434

 Brain metastases (+/-)

0.87

(0.13, 2.41)

0.787

1.73

(0.46, 6.48)

0.418

 Bone metastases ( +/-)

2.79

(0.94, 8.28)

0.065

2.40

(0.45, 12.69)

0.304

 Liver metastases (+/-)

3.83

(1.02, 14.30)

0.046

0.42

(0.03, 5.23)

0.503

OS

 Age (≥ 75/ < 74)

0.98

(0.19, 5.09)

0.977

6.72

(0.62, 73.39)

0.118

 Gender (male/female)

0.85

(0.16, 4.48)

0.850

0.89

(0.16, 5.02)

0.896

 ECOG performance status (2-3/0-1)

1.29 × 10^–8

(0.00, INF)

0.999

3.32 × 10^–10

(0.00, INF)

0.998

 EGFR mutation status (L858R or other/exon 19 deletion)

1.75

(0.39, 7.90)

0.464

3.26

(0.81, 13.13)

0.097

 PE ( +/-)

1.33

(0.30, 5.92)

0.713

0.95

(0.21, 4.32)

0.946

 Brain metastases (+/-)

3.85

(0.46, 32.01)

0.213

1.77

(0.45, 7.05)

0.416

 Bone metastases (+/-)

2.65

(0.51, 13.64)

0.245

3.83

(0.45, 34.19)

0.215

 Liver metastases ( +/-)

3.91

(0.74, 20.72)

0.109

0.97

(0.07, 13.51)

0.982

T790M positive patients

 PFS

 Age (≥ 75/ < 74)

1.32

(0.49, 3.53)

0.577

0.88

(0.27, 2.88)

0.835

 Gender (male/female)

0.52

(0.20, 1.36)

0.181

0.83

(0.26, 2.61)

0.744

 ECOG performance status (2-3/0-1)

2.50

(0.94, 6.65)

0.067

1.85

(0.36, 9.65)

0.463

 EGFR mutation status (L858R or other/exon 19 deletion)

2.09

(0.80, 5.47)

0.134

1.70

(0.46, 6.36)

0.428

 PE (+/-)

4.04

(1.43, 10.92)

0.006

7.31

(2.05, 26.03)

0.002

 Brain metastases (+/-)

1.50

(0.60, 3.74)

0.383

2.82

(0.71, 11.27)

0.142

 Bone metastases ( +/-)

1.39

(0.55, 3.50)

0.491

0.38

(0.05, 2.65)

0.329

 Liver metastases ( +/-)

1.35

(0.39, 4.70)

0.637

1.31

(0.22, 7.89)

0.766

OS

 Age (≥ 75/ < 74)

1.10

(0.35, 3.47)

0.877

1,72

(0.40, 7.49)

0.468

 Gender (male/female)

0.24

(0.05, 1.05)

0.058

0.33

(0.05, 2.00)

0.226

 ECOG performance status (2-3/0-1)

4.54

(1.44, 14.32)

0.010

5.12

(0.86, 30.34)

0.072

 EGFR mutation status (L858R or other/exon 19 deletion)

1.75

(0.56, 5.51)

0.337

0.74

(0.14,4.07)

0.732

 PE (+/-)

3.82

(1.34, 10.85)

0.012

4.11

(1.08, 15.62)

0.038

 Brain metastases (+/-)

0.95

(0.34, 2.67)

0.920

0.72

(0.17, 3.09)

0.657

 Bone metastases (+/-)

2.70

(0.95, 7.68)

0.062

1.13

(0.13, 9.80)

0.915

 Liver metastases ( +/-)

3.50

(1.04, 11.73)

0.043

1.61

(0.22, 11.68)

0.640